De Novo Discovery of Serotonin N -Acetyltransferase Inhibitors

Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, United States
Journal of Medicinal Chemistry (Impact Factor: 5.45). 12/2007; 50(22):5330-8. DOI: 10.1021/jm0706463
Source: PubMed


Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) is a member of the GCN5 N-acetyltransferase (GNAT) superfamily and catalyzes the penultimate step in the biosynthesis of melatonin; a large daily rhythm in AANAT activity drives the daily rhythm in circulating melatonin. We have used a structure-based computational approach to identify the first druglike and selective inhibitors of AANAT. Approximately 1.2 million compounds were virtually screened by 3D high-throughput docking into the active site of X-ray structures for AANAT, and in total 241 compounds were tested as inhibitors. One compound class, containing a rhodanine scaffold, exhibited low micromolar competitive inhibition against acetyl-CoA (AcCoA) and proved to be effective in blocking melatonin production in pineal cells. Compounds from this class are predicted to bind as bisubstrate inhibitors through interactions with the AcCoA and serotonin binding sites. Overall, this study demonstrates the feasibility of using virtual screening to identify small molecules that are selective inhibitors of AANAT.

Download full-text


Available from: David C. Klein,

Click to see the full-text of:

Article: De Novo Discovery of Serotonin N -Acetyltransferase Inhibitors

1.4 MB

See full-text
  • Source
    • "65 As well as inhibiting PI3K, thiazolidinedione derivatives are clinically used PPARγ agonists (pioglitazone, rosiglitazone) and aldose reductase inhibitors (epalrestat), and have research applications as antibacterial, antimalarial, anti-inflammatory, antiviral, herbicidal, insecticidal, antifungal, anticancer, anthelmintic agents, and for the treatment of Alzheimer’s disease, central nervous systems (CNS) disorders, diabetes, cardiovascular, cystic fibrosis and thrombocytopenia.63, 66 They bind to targets as diverse as G protein-coupled receptor 40 (GPR40),67 protein tyrosine phosphatase 3 (PRL-3),68 cyclooxygenase 2 (COX-2),69 the peptidoglycan biosynthesis enzymes, MurB, MurC and MurG,63 B cell lymphoma-2 (Bcl-2),70 phosphodiesterase 4 (PDE4),71 fungal protein mannosyl transferase 1 (PMT1),72 tumor necrosis factor alpha (TNF-α),73 hepatitis C virus nonstructural protein 3 (HCV NS3) and NS5b polymerase (HCV NS5b),74, 75 cytosolic phospholipase A2α (cPLA2α),76 proto-oncogene serine/threonine protein kinase (Pim-1),77 cyclin-dependent kinase 2 (CDK2),54 HIV-1 integrase,78 serotonin N-acetyltransferase (AANAT),79 and glycogen synthase kinase-3β (GSK-3β).80 Several of the most potent compounds identified here have also been picked up in other screening campaigns, offering a cautionary note to the possibility of off-target effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of synthesized and commercially available compounds were assessed against PI3Kα for in vitro inhibitory activity and the results compared to binding calculated in silico. Using published crystal structures of PI3Kγ and PI3Kδ co-crystallized with inhibitors as a template, docking was able to identify the majority of potent inhibitors from a decoy set of 1000 compounds. On the other hand, PI3Kα in the apo-form, modeled by induced fit docking, or built as a homology model gave only poor results. A PI3Kα homology model derived from a ligand-bound PI3Kδ crystal structure was developed that has a good ability to identify active compounds. The docking results identified binding poses for active compounds that differ from those identified to date and can contribute to our understanding of structure–activity relationships for PI3K inhibitors.
    ChemMedChem 03/2011; 6(3):514-22. DOI:10.1002/cmdc.201000467 · 2.97 Impact Factor
  • Source
    • "Each of the three inhibitors C646, C146, and C375 was further analyzed versus other acetyltransferases for specificity (Supplementary Table 2). We looked at serotonin Nacetyltransferase (Szewczuk et al., 2007), PCAF histone acetyltransferase (Lau et al., 2000), GCN5 histone acetyltransferase (Poux et al., 2002), Rtt109 histone acetyltransferase (Tang et al., 2008), Sas histone acetyltransferase (Shia et al., 2005), and MOZ histone acetyltransferase (Holbert et al., 2007). While compound C646 at 10 μM was highly selective in inhibiting p300 (86% inhibition) versus the other six acetyltransferases (less than 10% inhibition), C146 and C375 were less selective, inhibiting at least one of these enzymes with comparable potency to their p300 blockade (Supplementary Table 2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-site-directed small molecule inhibitor is not yet known. Here we use a structure-based, in silico screening approach to identify a commercially available pyrazolone-containing small molecule p300 HAT inhibitor, C646. C646 is a competitive p300 inhibitor with a K(i) of 400 nM and is selective versus other acetyltransferases. Studies on site-directed p300 HAT mutants and synthetic modifications of C646 confirm the importance of predicted interactions in conferring potency. Inhibition of histone acetylation and cell growth by C646 in cells validate its utility as a pharmacologic probe and suggest that p300/CBP HAT is a worthy anticancer target.
    Chemistry & biology 05/2010; 17(5):471-82. DOI:10.1016/j.chembiol.2010.03.006 · 6.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of nine 5-arylidenerhodanine derivatives was prepared in good yields and purity without the use of a solvent or catalyst under microwave-assisted condensation with some substituted isatins. All 5-arylidenerhodanines were evaluated as possible inhibitors of the CK1α/β, CDK5/p25, and GSK-3α/β kinases. None of them showed substantive inhibitory activity against these kinases when evaluated at the concentration of 10 μM. Keywordsrhodanine–isatin–Knoevenagel condensation–solvent-free microwave
    Chemical Papers- Slovak Academy of Sciences 06/2010; 65(3):332-337. DOI:10.2478/s11696-010-0104-9 · 1.47 Impact Factor
Show more